#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17846	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2110	837.9	0	.	n	.	0	A69G	SNP	69	69	A	365	365	G	969	G	897	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17846	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2110	837.9	0	.	n	.	0	C1450T	SNP	1450	1450	C	1746	1746	T	970	T,C	893,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	17846	16S	1529	1529	99.87	16S.l15.c4.ctg.1	2110	837.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1480	1480	C	1023	C	946	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32342	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3551	905.2	0	.	n	.	0	T695C	SNP	695	695	T	1003	1003	C	940	C,T	880,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32342	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3551	905.2	0	.	n	.	0	T1971C	SNP	1971	1971	T	2279	2279	C	1001	C,T	927,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32342	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3551	905.2	1	SNP	n	A2045G	0	.	.	2045	2045	A	2353	2353	A	1044	A	978	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	32342	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3551	905.2	1	SNP	n	C2597T	0	.	.	2597	2597	C	2905	2905	C	978	C,G	922,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2128	folP	855	855	100.0	folP.l6.c4.ctg.1	1652	128.0	1	SNP	p	R229S	1	.	.	685	687	AGC	1047	1049	AGC	194;193;193	A,G;G;C	186,1;184;182	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5616	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3379	165.3	1	SNP	p	S91F	1	.	.	271	273	TTC	585	587	TTC	190;190;191	T;T;C	181;181;183	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5616	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3379	165.3	1	SNP	p	D95G	1	.	.	283	285	GGC	597	599	GGC	188;186;187	G;G,A;C	181;177,1;176	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5616	gyrA	2751	2751	100.0	gyrA.l15.c17.ctg.1	3379	165.3	1	SNP	p	G95N	0	.	.	283	285	GGC	597	599	GGC	188;186;187	G;G,A;C	181;177,1;176	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1762	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1268	138.0	0	.	p	.	0	D79N	NONSYN	235	237	GAT	549	551	AAT	212;211;213	A;A;T	197;193;191	.	.
mtrR.WHO_U_01459	mtrR.WHO_U_01459	1	1	539	1762	mtrR	633	633	99.84	mtrR.l15.c4.ctg.1	1268	138.0	1	SNP	p	G45D	0	.	.	133	135	GGC	447	449	GGC	209;210;210	G;G;C	196;198;197	mtrR.WHO_U_01459:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	924	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1162	79.0	0	.	n	.	0	A197.	DEL	197	197	A	603	603	A	206	A	194	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5030	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2950	169.2	0	.	p	.	0	E91G	NONSYN	271	273	GAG	625	627	GGG	201;202;199	G;G,A;G	191;187,1;186	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5030	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2950	169.2	1	SNP	p	D86N	0	.	.	256	258	GAC	610	612	GAC	194;195;197	G;A;C	183;176;186	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5030	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2950	169.2	1	SNP	p	S87R	0	.	.	259	261	AGT	613	615	AGT	198;199;197	A;G;T	184;186;181	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5030	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2950	169.2	1	SNP	p	S87W	0	.	.	259	261	AGT	613	615	AGT	198;199;197	A;G;T	184;186;181	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5030	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2950	169.2	1	SNP	p	S87I	0	.	.	259	261	AGT	613	615	AGT	198;199;197	A;G;T	184;186;181	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	5030	parC	2304	2304	99.87	parC.l15.c17.ctg.1	2950	169.2	1	SNP	p	S88P	0	.	.	262	264	TCC	616	618	TCC	195;196;196	T;C;C	179;181;185	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4718	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2776	169.0	0	.	p	.	0	R427H	NONSYN	1279	1281	CGC	1663	1665	CAC	239;237;236	C;A,G;C	215;212,1;217	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	4718	parE	1986	1986	99.9	parE.l15.c4.ctg.1	2776	169.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1612	1614	GGC	219;222;223	G,C;G;C	205,1;206;206	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	539	4652	penA	1749	1749	99.94	penA.l15.c30.ctg.1	2502	184.9	0	.	p	.	0	A502T	NONSYN	1504	1506	GCG	1849	1851	ACG	245;245;244	A;C;G	198;204;196	.	.
penA.2.002	penA.2.002	1	1	539	4652	penA	1749	1749	99.94	penA.l15.c30.ctg.1	2502	184.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1276	1278	GCA	231;236;238	G;C;A	219;226;227	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	539	4652	penA	1749	1749	99.94	penA.l15.c30.ctg.1	2502	184.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1279	1281	ATC	239;237;240	A;T;C	231;227;227	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	539	4652	penA	1749	1749	99.94	penA.l15.c30.ctg.1	2502	184.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1291	1293	GTG	232;233;234	G;T;G	224;223;223	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	539	4652	penA	1749	1749	99.94	penA.l15.c30.ctg.1	2502	184.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1291	1293	GTG	232;233;234	G;T;G	224;223;223	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	539	4652	penA	1749	1749	99.94	penA.l15.c30.ctg.1	2502	184.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1795	1797	ACC	229;228;229	A;C;C	209;215;217	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	539	4652	penA	1749	1749	99.94	penA.l15.c30.ctg.1	2502	184.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1972	1974	GGC	198;196;194	G;G;C	182;180;176	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	539	4652	penA	1749	1749	99.94	penA.l15.c30.ctg.1	2502	184.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1981	1983	GGC	195;195;195	G;G;C	177;174;174	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	539	4652	penA	1749	1749	99.94	penA.l15.c30.ctg.1	2502	184.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1999	2001	CCG	160;165;164	C,G;C;G	125,4;128;131	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6658	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	2969	222.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1616	1618	CCG	209;206;201	C;C;G	178;186;178	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2346	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1790	130.1	0	.	p	.	0	M83fs	FSHIFT	247	247	A	510	510	C	179	C	163	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	H217N	NONSYN	649	651	CAT	346	348	AAT	15;13;12	A;A;T	15;13;12	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	D218N	NONSYN	652	654	GAT	349	351	AAT	12;13;13	A;A;T	12;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	V226A	NONSYN	676	678	GTA	373	375	GCA	15;15;17	G;C;A	15;15;17	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	.	MULTIPLE	700	702	ACT	396	398	GTA	17;17;17	G;T;A	17;17;17	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	S236N	NONSYN	706	708	AGC	402	404	AAC	17;17;18	A;A;C	17;17;18	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	.	MULTIPLE	709	711	AAC	406	410	TGGCG	18;18;19;26;28	T;G;G;C;G	18;18;18;25;26	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	D238A	NONSYN	712	714	GAT	412	414	GCT	31;32;33	G;C;T	29;30;30	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	V258L	NONSYN	772	774	GTA	472	474	TTA	63;64;64	T;T;A	56;57;57	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	517	519	CAT	71;67;64	C;A;T	66;64;61	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	D274S	NONSYN	820	822	GAT	520	522	AGT	64;64;64	A;G;T	61;61;60	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	362	porB1a	984	297	90.37	porB1a.l15.c30.ctg.2	618	22.0	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	529	531	TAC	62;62;62	T;A;C	61;61;60	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	0	.	p	.	0	T26A	NONSYN	76	78	ACC	404	406	GCC	312;313;313	G;C;C	289;289;288	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	0	.	p	.	0	N38E	NONSYN	112	114	AAT	440	442	GAA	289;285;286	G;A;A	267;265;264	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	0	.	p	.	0	N124S	NONSYN	370	372	AAT	698	700	AGT	239;240;240	A;G,A;T	223;226,1;227	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	0	.	p	.	0	N134D	NONSYN	400	402	AAT	728	730	GAT	266;268;269	G,A;A;T	248,1;251;252	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	0	.	p	.	0	P175S	NONSYN	523	525	CCA	851	853	TCA	295;298;302	T;C;A	268;271;274	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	0	.	p	.	0	A218V	NONSYN	652	654	GCC	980	982	GTC	280;281;276	G;T;C	252;253;253	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	0	.	p	.	0	F222S	NONSYN	664	666	TTT	992	994	TCT	267;264;269	T;C;T	247;245;250	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1310	1312	GCA	275;279;285	G;C;A	250;253;261	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	1	SNP	p	G120K	1	.	.	358	360	AAG	686	688	AAG	231;227;225	A;A;G	222;216;215	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	1	SNP	p	D121N	0	.	.	361	363	GAC	689	691	GAC	228;228;228	G;A;C	215;214;212	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3540	porB1b	1047	1047	99.04	porB1b.l15.c4.ctg.1	1519	231.1	1	SNP	p	A121D	1	.	.	361	363	GAC	689	691	GAC	228;228;228	G;A;C	215;214;212	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	13712	rpoB	4179	4179	100.0	rpoB.l15.c4.ctg.1	4834	282.2	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1939	1941	CAT	324;324;324	C;A;T,C	304;305;302,1	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1458	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1035	139.2	1	SNP	p	V57M	1	.	.	169	171	ATG	473	475	ATG	321;322;319	A;T;G	304;308;302	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
